Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Expenses
$75,000
What this organization spent lobbying with its own staff.
Reported using IRS section 6033(b)(8) definitions (method B): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
District of Columbia
Lobbyists on this filing
3
-
ANNA HYDEPreviously held: Vice President, Advocacy and Access
-
ALISA VIDULICH CASAVANT New on this filingPreviously held: Policy Director
-
HAYLEY DEMPSEY New on this filingPreviously held: Federal Affairs Manager
Government bodies contacted
10
Lobbying activity
3
Medicaid
340B S.46 - Health Care Affordability Act of 2025 Safe Step Act H.R.5509 S.864 - HELP Copays Act PBM Reform Act of 2025 PAAT Act "Patient Access to Autoimmune Treatments Act" Ensuring Patient Access to Critical Breakthrough Products Act CDC Arthritis Program - Appropriations Congressionally Directed Medical Research Program - Appropriations ATPCs Arthritis Research Medicaid H.R. 4299, "the Protecting Patient Access to Cancer and Complex Therapies Act"
CDC Arthritis Program - Appropriations Congressionally Directed Medical Research Program - Appropriations H.R.1, the One Big Beautiful Bill